SG11201804395PA - Pharmaceutical compositions comprising levodopa amide and uses thereof - Google Patents
Pharmaceutical compositions comprising levodopa amide and uses thereofInfo
- Publication number
- SG11201804395PA SG11201804395PA SG11201804395PA SG11201804395PA SG11201804395PA SG 11201804395P A SG11201804395P A SG 11201804395PA SG 11201804395P A SG11201804395P A SG 11201804395PA SG 11201804395P A SG11201804395P A SG 11201804395PA SG 11201804395P A SG11201804395P A SG 11201804395PA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- rehovot
- pharmaceutical compositions
- publication
- date
- Prior art date
Links
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 title abstract 3
- 229960004502 levodopa Drugs 0.000 title abstract 3
- -1 levodopa amide Chemical class 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract 2
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 229960003638 dopamine Drugs 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Psychology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 1 June 2017 (01.06.2017) WIPOIPCT (10) International Publication Number WO 2017/090039 A3 (51) International Patent Classification: A61K9/00 (2006.01) A61K 47/26 (2006.01) A61K 47/12 (2006.01) A61K 9/06 (2006.01) A61K 47/18 (2017.01) A61K31/00 (2006.01) (21) International Application Number: PCT/IL2016/051261 (22) International Filing Date: (25) Filing Language: (26) Publication Language: 23 November 2016 (23.11.2016) English English (30) Priority Data: 62/259,324 24 November 2015 (24.11.2015) US (71) Applicant: NEURODERM LTD. [IL/IL]; 3 Pekeris St., Rabin Science Park, 7670212 Rehovot (IL). (72) Inventors: YACOBY-ZEEVI, Oron; 204 Hanarkissim St., 6094600 Moshav Bitsaron (IL). NEMES, Mara; 17/4 Haatsmaut St., 7047219 Gedera (IL). ZWOZNIK, Eduardo; 6 Netiv Hashayarot St., 7680400 Mazkeret Batya (IL). VAINSHTOK, Irena; 47/2 Ben Zion Blvd., Rehovot (IL). SELA, Einat; 4A Harav Moshe Zvi Neria St., Rehovot (IL). (74) Agents: AVITAL, Avihu et al.; BEN-AMI & ASSOCI ATES, P.O. Box 94, 7610002 Rehovot (IL). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) (88) Date of publication of the international search report: 31 August 2017 ON ON n O (54) Title: PHARMACEUTICAL COMPOSITIONS COMPRISING LEVODOPA AMIDE AND USES THEREOF (57) : The present invention discloses various aqueous pharmaceutical compositions comprising a levodopa amide com pound, or a salt thereof, which are stable for at least 24 hours at room temperature, and use thereof in treatment of diseases or dis orders characterized by neurodegeneration and/or reduced levels of brain dopamine, e.g., Parkinson's disease.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562259324P | 2015-11-24 | 2015-11-24 | |
| PCT/IL2016/051261 WO2017090039A2 (en) | 2015-11-24 | 2016-11-23 | Pharmaceutical compositions comprising levodopa amide and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201804395PA true SG11201804395PA (en) | 2018-06-28 |
Family
ID=57590758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201804395PA SG11201804395PA (en) | 2015-11-24 | 2016-11-23 | Pharmaceutical compositions comprising levodopa amide and uses thereof |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20170296491A1 (en) |
| EP (1) | EP3380076A2 (en) |
| JP (1) | JP2018535230A (en) |
| CN (1) | CN108495617A (en) |
| AU (1) | AU2016358511A1 (en) |
| BR (1) | BR112018010564A2 (en) |
| CA (1) | CA3006028A1 (en) |
| CL (1) | CL2018001395A1 (en) |
| IL (1) | IL259484A (en) |
| RU (1) | RU2018119194A (en) |
| SG (1) | SG11201804395PA (en) |
| WO (1) | WO2017090039A2 (en) |
| ZA (1) | ZA201803485B (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10258585B2 (en) | 2014-03-13 | 2019-04-16 | Neuroderm, Ltd. | DOPA decarboxylase inhibitor compositions |
| DK3777833T3 (en) | 2014-03-13 | 2023-12-18 | Neuroderm Ltd | DOPA DECARBOXYLASE INHIBITOR COMPOSITIONS |
| WO2019038637A1 (en) | 2017-08-21 | 2019-02-28 | Neuroderm Ltd | Crystalline salt forms of levodopa amide and methods of making and using same |
| WO2019038638A1 (en) | 2017-08-21 | 2019-02-28 | Neuroderm Ltd | Process for preparing purified levodopa amide |
| WO2019038639A1 (en) | 2017-08-21 | 2019-02-28 | Neuroderm Ltd | Crystalline levodopa amide free base and methods of making and using same |
| WO2019145773A1 (en) | 2017-12-15 | 2019-08-01 | Nos Life Sciences Corporation | Liposomal-encapsulated formulations |
| WO2020178810A1 (en) * | 2019-03-04 | 2020-09-10 | Neuroderm, Ltd. | Pharmaceutical compositions comprising levodopa amide derivatives and uses thereof |
| WO2020214886A1 (en) * | 2019-04-17 | 2020-10-22 | Vici Health Sciences LLC | Liquid pharmaceutical compositions |
| KR20220103918A (en) * | 2019-09-05 | 2022-07-25 | 뉴로덤 엘티디 | Liquid compositions comprising levodopa amino acid conjugates and uses thereof |
| JP7506371B2 (en) | 2020-01-20 | 2024-06-26 | 国立大学法人浜松医科大学 | Dopamine depletion inhibitors |
| US11331293B1 (en) | 2020-11-17 | 2022-05-17 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
| US11213502B1 (en) | 2020-11-17 | 2022-01-04 | Neuroderm, Ltd. | Method for treatment of parkinson's disease |
| US11844754B2 (en) | 2020-11-17 | 2023-12-19 | Neuroderm, Ltd. | Methods for treatment of Parkinson's disease |
| CN116270675A (en) * | 2023-03-21 | 2023-06-23 | 山东省分析测试中心 | Application of N-acetamido glucose in preventing and treating MPTP-induced neuronal damage |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004069146A2 (en) * | 2003-02-07 | 2004-08-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | L-dopa amide derivatives and uses thereof |
| KR101641401B1 (en) | 2009-05-19 | 2016-07-20 | 뉴로덤 엘티디 | Compositions for continuous administration of DOPA decarboxylase inhibitors |
| JP2014508113A (en) * | 2010-12-10 | 2014-04-03 | シンアジャイル コーポレーション | Levodopaprodrug composition capable of subcutaneous injection and injection method |
| US20150217046A1 (en) * | 2012-06-05 | 2015-08-06 | Synagile Corporation | Dosing regimens for subcutaneously infusible acidic compositions |
-
2016
- 2016-11-23 CA CA3006028A patent/CA3006028A1/en not_active Abandoned
- 2016-11-23 WO PCT/IL2016/051261 patent/WO2017090039A2/en active Application Filing
- 2016-11-23 CN CN201680079822.0A patent/CN108495617A/en not_active Withdrawn
- 2016-11-23 JP JP2018526784A patent/JP2018535230A/en active Pending
- 2016-11-23 AU AU2016358511A patent/AU2016358511A1/en not_active Abandoned
- 2016-11-23 RU RU2018119194A patent/RU2018119194A/en not_active Application Discontinuation
- 2016-11-23 EP EP16816418.4A patent/EP3380076A2/en not_active Withdrawn
- 2016-11-23 BR BR112018010564-3A patent/BR112018010564A2/en not_active IP Right Cessation
- 2016-11-23 US US15/360,165 patent/US20170296491A1/en not_active Abandoned
- 2016-11-23 SG SG11201804395PA patent/SG11201804395PA/en unknown
-
2018
- 2018-05-21 IL IL259484A patent/IL259484A/en unknown
- 2018-05-24 CL CL2018001395A patent/CL2018001395A1/en unknown
- 2018-05-25 ZA ZA2018/03485A patent/ZA201803485B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3380076A2 (en) | 2018-10-03 |
| AU2016358511A1 (en) | 2018-06-21 |
| CN108495617A (en) | 2018-09-04 |
| US20170296491A1 (en) | 2017-10-19 |
| WO2017090039A2 (en) | 2017-06-01 |
| CL2018001395A1 (en) | 2018-10-12 |
| RU2018119194A3 (en) | 2020-04-20 |
| RU2018119194A (en) | 2019-12-25 |
| WO2017090039A3 (en) | 2017-08-31 |
| ZA201803485B (en) | 2019-08-28 |
| CA3006028A1 (en) | 2017-06-01 |
| BR112018010564A2 (en) | 2018-11-21 |
| JP2018535230A (en) | 2018-11-29 |
| IL259484A (en) | 2018-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201804395PA (en) | Pharmaceutical compositions comprising levodopa amide and uses thereof | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201908547VA (en) | Hydrogel cross-linked hyaluronic acid prodrug compositions and methods | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201907034PA (en) | Methods of treating influenza | |
| SG11201807573VA (en) | Methods for providing single-stranded rna | |
| SG11201811470PA (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
| SG11201908994RA (en) | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy | |
| SG11201901700UA (en) | Biaryl compounds useful as immunomodulators | |
| SG11201809082WA (en) | Nlrp3 modulators | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201810579YA (en) | Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders | |
| SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
| SG11201907604UA (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan | |
| SG11201810177VA (en) | Pet-imaging immunomodulators | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201906959RA (en) | Aryl hydrocarbon receptor (ahr) modulator compounds | |
| SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201906958TA (en) | Aryl hydrocarbon receptor (ahr) modulator compounds | |
| SG11201809341PA (en) | Mobile robot | |
| SG11201900021PA (en) | Methods and compositions for the treatment of cancer | |
| SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
| SG11201809172WA (en) | Crystalline forms of n-[2-(3-hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2h-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide | |
| SG11201806852PA (en) | Protein purification |